162 related articles for article (PubMed ID: 33627833)
21. Unrelated donor bone marrow transplantation for hematological malignancies-current status.
Davies SM; Wagner JE; Weisdorf DJ; Shu XO; Blazar BR; Enright H; McGlave PB; Ramsay NK
Leuk Lymphoma; 1996 Oct; 23(3-4):221-6. PubMed ID: 9031102
[TBL] [Abstract][Full Text] [Related]
22. The recipient CXCL10 + 1642C>G variation predicts survival outcomes after HLA fully matched unrelated bone marrow transplantation.
Nakata K; Takami A; Espinoza JL; Matsuo K; Morishima Y; Onizuka M; Fukuda T; Kodera Y; Akiyama H; Miyamura K; Mori T; Nakao S;
Clin Immunol; 2013 Feb; 146(2):104-11. PubMed ID: 23291247
[TBL] [Abstract][Full Text] [Related]
23. Unc93b1 is essential for cytokine activation of five PAMPs in the orange-spotted grouper (Epinephelus coioides).
Liang Y; Wang Y; He L; He J; Peng W; Zhou L; Zhang Y; Zhang H; Shi H; Lin H; Lu D
Dev Comp Immunol; 2018 Apr; 81():8-18. PubMed ID: 29097235
[TBL] [Abstract][Full Text] [Related]
24. P2X7 receptor polymorphism and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation.
Lee KH; Park SS; Kim I; Kim JH; Ra EK; Yoon SS; Hong YC; Park S; Kim BK
Haematologica; 2007 May; 92(5):651-7. PubMed ID: 17488689
[TBL] [Abstract][Full Text] [Related]
25. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.
Symons HJ; Leffell MS; Rossiter ND; Zahurak M; Jones RJ; Fuchs EJ
Biol Blood Marrow Transplant; 2010 Apr; 16(4):533-42. PubMed ID: 19961944
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic bone marrow transplantation for hematological malignancies--controversies and recent advances.
Ringdén O
Acta Oncol; 1997; 36(6):549-64. PubMed ID: 9408144
[TBL] [Abstract][Full Text] [Related]
27. NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation.
Jaskula E; Lange A; Kyrcz-Krzemien S; Markiewicz M; Dzierzak-Mietla M; Jedrzejczak WW; Czajka P; Mordak-Domagala M; Lange J; Gronkowska A; Nowak J; Warzocha K; Hellmann A; Kowalczyk J; Drabko K; Gozdzik J; Mizia S;
Biol Blood Marrow Transplant; 2014 Mar; 20(3):409-14. PubMed ID: 24345423
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.
Lee SJ; Logan B; Westervelt P; Cutler C; Woolfrey A; Khan SP; Waller EK; Maziarz RT; Wu J; Shaw BE; Confer D; Horowitz MM; Anasetti C
JAMA Oncol; 2016 Dec; 2(12):1583-1589. PubMed ID: 27532508
[TBL] [Abstract][Full Text] [Related]
29. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
30. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation.
Geller RB; Devine SM; O'Toole K; Persons L; Keller J; Mauer D; Holland HK; Dix SP; Piotti M; Redei I; Connaghan G; Heffner LT; Hillyer CD; Waller EK; Winton EF; Wingard JR
Bone Marrow Transplant; 1997 Aug; 20(3):219-25. PubMed ID: 9257890
[TBL] [Abstract][Full Text] [Related]
32. Association of
Li J; Seligson N; Zhang X; Johnson J; Vangundy Z; Wang D; Phelps M; Hofmeister C; Sadee W; Poi MJ
Anticancer Res; 2020 Oct; 40(10):5707-5713. PubMed ID: 32988896
[TBL] [Abstract][Full Text] [Related]
33. Vitamin D receptor gene polymorphism associates with graft-versus-host disease and survival in HLA-matched sibling allogeneic bone marrow transplantation.
Middleton PG; Cullup H; Dickinson AM; Norden J; Jackson GH; Taylor PR; Cavet J
Bone Marrow Transplant; 2002 Aug; 30(4):223-8. PubMed ID: 12203138
[TBL] [Abstract][Full Text] [Related]
34. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
Zilberberg J; Feinman R; Korngold R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643
[TBL] [Abstract][Full Text] [Related]
35. Haploidentical stem cell transplantation vs matched unrelated donor transplantation in adults with hematologic malignancies: a systematic review and meta-analysis.
Ma L; Han X; Jiang S; Meng Q; Zhang L; Bao H
Hematology; 2020 Dec; 25(1):356-365. PubMed ID: 33054609
[TBL] [Abstract][Full Text] [Related]
36. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation.
Waller EK; Rosenthal H; Jones TW; Peel J; Lonial S; Langston A; Redei I; Jurickova I; Boyer MW
Blood; 2001 May; 97(10):2948-56. PubMed ID: 11342416
[TBL] [Abstract][Full Text] [Related]
37. Survival after transplantation of unrelated donor umbilical cord blood is comparable to that of human leukocyte antigen-matched unrelated donor bone marrow: results of a matched-pair analysis.
Barker JN; Davies SM; DeFor T; Ramsay NK; Weisdorf DJ; Wagner JE
Blood; 2001 May; 97(10):2957-61. PubMed ID: 11342417
[TBL] [Abstract][Full Text] [Related]
38. UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes.
Kim YM; Brinkmann MM; Paquet ME; Ploegh HL
Nature; 2008 Mar; 452(7184):234-8. PubMed ID: 18305481
[TBL] [Abstract][Full Text] [Related]
39. Comparable long-term outcome of unrelated cord blood transplantation with related bone marrow or peripheral blood stem cell transplantation in patients aged 45 years or older with hematologic malignancies after myeloablative conditioning.
Konuma T; Kato S; Ooi J; Oiwa-Monna M; Kawamata T; Tojo A; Takahashi S
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1150-5. PubMed ID: 24727335
[TBL] [Abstract][Full Text] [Related]
40. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
